Business Wire

B2BROKER

17.2.2020 11:02:04 CET | Business Wire | Press release

Share
B2Broker Introduces B2Core To Offer Businesses Brand New Pack-Based Trader’s Room Concept

B2Broker , a leading liquidity and technology provider of solutions to the forex and crypto industry, is pleased to introduce B2Core , a major upgrade to its client cabinet solution Trader’s Room, which has undergone a major overhaul in response to client demand and to meet today’s exacting business needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005010/en/

All New Client Cabinet Concept

B2Core takes on a whole new guise embracing a vast new range of new capabilities, culminating in an innovative and unique bespoke service for clients. B2Core offers an all-round, greatly improved user experience compared with the company’s previous version. It consolidates all previous aspects of Traders room, including clients area, etc, elevating the company’s existing SaaS solution to the top of its league in the financial services industry.

Businesses looking for a solution with functionality that can handle a broader and more customised range of demands than the industry-standard traders room solution will find B2Core exceeds their expectations and outperforms other products in the market with a range of advanced features that can be tailored to fit each type of organisation. With B2Core, businesses no longer need to accept a one-size-fits-all solution.

Unique Pack-Based Solution

From basic tasks such as organising the work of forex brokers and crypto exchanges, back office for employees and administrators, front-end for traders, verification and registration of customers and a huge range of payment functions, B2Core brings to the market a whole new concept of a pack-based solution.

This essentially means that B2Core clients can now choose a package that suits their requirements best. For example, the B2Core Standard pack includes a basic set of features and offers a budget-friendly solution. Alternatively, businesses can opt for an Advanced pack with many more potential features and modules such as bonuses, IB Room and Converter, and integrations with a large choice of payment solutions and external platforms such as B2Trader, MetaTrader, CTrader, dxTrade, AlphaPoint, OneZero and PrimeXM.

At the top end of the scale for larger corporates, B2Core offers an Enterprise pack, a solution which is ideal for where the client has their own specific requirements and demands regarding the type of solution they want. In this respect, B2Broker develops and maintains the solution accordingly.

The newly adapted B2Core pack-based solution means that B2Broker can offer a product which is more responsive to its clients requirements and more flexible in that the solution can be adjusted to meet a wide range of needs.

B2Core is a must-have choice for any professional business including FX and crypto brokers, converters, spot and margin exchanges, EMIs and crypto wallets, adding an extra dimension to the existing Trader’s Room offering with the following all-important features:

Dynamic Advanced UI Layout

The first of the new features is an ideal opportunity for all Exchange clients to obtain one of the most advanced front-end layouts on the market. The end-user of the Exchange will be able to fully customize the workspaces in order to maximize the efficiency of their trading performance and combine it with the satisfaction of usage.

For example, users can now organize the blocks of order books, watchlist, charts, history of trades, change the size and order of these windows without any limitations to get the best usability and maximum customization of the platform. It is also possible to create several workspaces to enable users to have separate areas for different trading purposes.

Another new feature is Market Depth which shows the market's ability to sustain relatively large market orders without impacting on the price of the asset in question. Market depth takes into consideration the overall level and breadth of current open orders within an individual currency pair.

Grouping of volumes is a significant part of the update which allows users to analyze the deepest liquidity available on the platform. It can be accessed in the order book of every instrument.

Finally, the Watchlist widget can now be added to the workspaces of the Trading UI. Users are able to make a list of the pairs that they wish to monitor and display the current prices, volumes and 24 hour highs & lows in one place.

Overall, the Trading UI is now capable of fulfilling all the demands of professional traders who frequently use it to monitor large amounts of information.

Advanced Anti-Fraud Homemade System

B2Core’s Advanced Anti-Fraud Homemade System is an automatic withdrawals system featuring security alerts and other procedures to avoid money-laundering and trading cheating procedures on the platform.

Sum-Sub WebSDK Integration

Sum-Sub WebSDK integration provides advanced and highly customizable Know Your Customer (KYC) procedures that will enable a business owner to avoid legal department costs as everything is handled automatically by the technology provider.

PrimeXM/OneZero Integration

As well as deep integration with the industry’s flagship trading platform MetaTrader 4 and 5, B2Core is now integrated with PrimeXM, OneZero, dxTrade and B2Trader, making a total of 6 trading platforms. B2Broker can now offer its customers the opportunity to target a wider range of end-customers across the globe.

Ticket System

B2Core, currently integrated with SupportPal, can now enable clients to offer a ticket-based customer support service within B2Core as a module. Rather than conducting support via Skype and other social networks where information is likely to get lost, using the Ticket System ensures everything is recorded and processed as part of the same procedure.

Detailed MT Analytics

B2Core’s main trading platform integration with MT 4 & 5 allows the end-users to monitor all activities occurring on the MT account directly from their Trader’s Room account. This allows the user to check his requirement and actions with one solution as illustrated:

Withdrawal Address Whitelist

A new whitelist function has been added which is essentially an address whitelist for withdrawal purposes. This is an additional security measure for end users, where they are able to specify their chosen, trusted wallets for withdrawal which means that only these wallets will be logged out of the system. The new security measure has been developed in conjunction with 2FA Google Authenticator.

A Multi-Featured Package To Suit Every Business Need

All in all, B2Core offers a huge range of vital new adjustable features, providing users with the means to pick and choose what suits them. It is the must-have solution for every company and one which is capable of handling client-facing operations of every type of financial business, regardless of complexity. Not only is B2Core highly-customisable, it is an efficient, high-performance system that overrides all the one-size-fits-all client cabinet solutions in the market, and most importantly, one which your users will thank you for choosing.

About B2Broker

B2Broker is a liquidity and technology provider of solutions for the crypto and foreign exchange (FX) industry. The company specialises in the sphere of B2B services and products, catering for a wide range of clients including large licensed brokers, crypto exchanges, crypto brokers, forex brokers, hedge and crypto funds and professional managers.

B2Broker’s advanced base of ready to use technical solutions enable brokers to save time and money on consuming infrastructure projects and focus on enlarging their client base and increasing their revenues.

Please contact B2Broker to enhance your company with B2Core.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye